Avalyn Pharma director reports 43,928-share option

Avalyn Pharma Inc. director Erin Lavelle filed an initial ownership report showing a stock option to buy 43,928 shares of common stock at an exercise price of $4.62 per share.

Rhea-AI Filing Summary

Avalyn Pharma Inc. director Erin Lavelle filed an initial ownership report showing a stock option to buy 43,928 shares of common stock at an exercise price of $4.62 per share. The option expires on July 23, 2034, and one-eighth of the underlying shares vest in substantially equal quarterly installments starting from July 24, 2024, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lavelle Erin

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 43,928 contracts (Direct)

Footnotes (1)

1. F1. 1/8th of the shares underlying this option vest and become exercisable in substantially equal quarterly installments on each quarterly anniversary of July 24, 2024, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option underlying shares: 43,928 shares Exercise price: $4.62 per share Shares following transaction: 43,928 shares +3 more

6 metrics

Option underlying shares 43,928 shares Underlying common stock for reported stock option holding

Exercise price $4.62 per share Exercise price of stock option on Avalyn Pharma common stock

Shares following transaction 43,928 shares Total stock option underlying shares reported as held directly

Option expiration date July 23, 2034 Expiration date of the reported stock option

Initial vesting reference date July 24, 2024 Quarterly vesting schedule starts from this date

Per-period vesting fraction 1/8 of shares Portion of underlying shares vesting in each quarterly installment

Key Terms

Stock Option (right to buy), Common Stock, vesting, exercise price

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"shares underlying this option vest and become exercisable in substantially equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 4.6200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Erin Lavelle’s Form 3 filing for Avalyn Pharma (AVLN) show?

The filing shows Erin Lavelle holds a stock option to purchase 43,928 shares of Avalyn Pharma common stock at $4.62 per share, expiring on July 23, 2034, with vesting tied to continued service after July 24, 2024.

How many Avalyn Pharma (AVLN) shares are covered by Erin Lavelle’s option?

Erin Lavelle’s reported stock option covers 43,928 shares of Avalyn Pharma common stock. These shares are not all available immediately; they vest in quarterly installments, with vesting dependent on her continued service with the company after July 24, 2024.

What is the exercise price of Erin Lavelle’s Avalyn Pharma (AVLN) stock option?

The exercise price of Erin Lavelle’s stock option is $4.62 per share. This means she can buy Avalyn Pharma common stock at $4.62 for each of the 43,928 underlying shares, subject to vesting and before the option’s July 23, 2034 expiration date.

When does Erin Lavelle’s Avalyn Pharma (AVLN) stock option expire?

The reported stock option held by Erin Lavelle expires on July 23, 2034. She may exercise vested portions of the 43,928-share option at $4.62 per share any time before that date, as long as vesting and service conditions are satisfied.

How does Erin Lavelle’s Avalyn Pharma (AVLN) option vest over time?

According to the footnote, 1/8 of the shares underlying Erin Lavelle’s option vest in substantially equal quarterly installments on each quarterly anniversary of July 24, 2024. Vesting continues only if she remains in service on each quarterly vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 06:47 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lavelle Erin

(Last) (First) (Middle)

105 W FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/29/2026

3. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	07/23/2034	Common Stock	43,928	$4.62	D

Explanation of Responses:

1. 1/8th of the shares underlying this option vest and become exercisable in substantially equal quarterly installments on each quarterly anniversary of July 24, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Douglas Carlson	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)